Babylon Biosciences
22 employees on LinkedIn · 7 known investors
Babylon is a digital health company that develops prescription medications and treatments for specific health conditions. The company's portfolio includes Xiidra, an FDA-approved eye drop for treating dry eye disease in adults.
Also known as Babylon · Babylon Bio
Founders & leadership
Board
Investors · 7
Company profile
researched Aug 2026Babylon Biosciences (babylon.bio) is a privately held biotechnology company headquartered in San Francisco, California, described by Caplight as developing small-molecule therapeutics for diseases of the brain, such as Alzheimer's disease. The company's own website frames its mission around "giving families more time with their loved ones" and lists news items concerning Alzheimer's treatment development. Caplight lists the company as founded in 2023 with an employee range of 10, and associates it with keywords including drug discovery, small-molecule therapeutics, AI-driven and in silico drug discovery, clinical trial prediction and predictive modeling.
The company presents itself primarily through the credentials of its team and advisors rather than a disclosed pipeline. Sacha Schermerhorn is listed as CEO and founder, supported by functional groups the site labels diligence (chemistry, structural biology, pharmacology), discovery (chemistry, chemical biology), development/CMC, technical and portfolio (risk/capital) teams, including John Macor, Bill Greenlee, Dario Doller, Andy Ambrose, Edward Sun, Juliana McInnis, David Askin, Richard Libby, Pat Weber and Eric Parker. An advisory board comprises Steve Holtzman (business development), Michelle Arkin (chemistry) and Matt Krisiloff (operations/fundraising). The site aggregates team-level track record claims — 51 FDA-approved medicines, more than 650 patents, more than 210 clinical candidates, three ACS Medicinal Chemistry Hall of Famers and $78 billion in total acquisitions — and cites prior drugs associated with team members, including lisinopril (Merck, approved 1987), Nurtec ODT (Biohaven, acquired by Pfizer for $11.6 billion in 2022), Xiidra/lifitegrast (approved 2016; purchased by Novartis for $3.4 billion in 2019 and sold to Bausch + Lomb for $1.75 billion in 2023) and Zejula (Tesaro, acquired by GSK for $5.1 billion in 2019). These are historical achievements of team members at prior organizations, not assets of Babylon Biosciences.
Publicly available financial detail is limited. Caplight reports total funding raised of $500,000, a last round dated October 30, 2024 categorized as accelerator, and an earlier seed round dated August 1, 2024, with no disclosed amounts or valuations for either. No revenue, pipeline stage or clinical data are disclosed in the available sources.
Founding story
Sacha Schermerhorn is listed on the company website as CEO and founder. Caplight records 2023 as the year founded. The sources do not describe the circumstances of the company's founding.
Business model
Caplight classifies Babylon Biosciences as a B2B business in healthcare and life sciences, with a services-and-consulting customer profile and an application-layer AI positioning; F4 similarly labels it a B2B biotech at seed stage. The company's disclosed activity centers on discovering and developing small-molecule drug candidates, and its 2026 site news references in-licensing an asset (SAR444500) from Sanofi, indicating asset acquisition and development alongside internal discovery. No pricing, contract or customer terms are disclosed in the available sources.
Not disclosed in the available sources.
Traction
Disclosed traction is limited. Caplight reports $500,000 in total funding raised, with a seed round dated August 1, 2024 and an accelerator round dated October 30, 2024, and lists Andreessen Horowitz, Backwards Capital, Founders Fund, Lux Capital, Long Journey Ventures, Soma Capital and Mission BioCapital among investors; F4 lists four investors, naming Long Journey Ventures, Hack VC, K5 Global and Paradigm. Caplight also recorded an April 2026 signal of 207% month-over-month growth in monthly website visitors to 3.2K and places the company in the top 25% of tracked companies on its momentum index. The company's own news feed cites an in-licensing of Sanofi's SAR444500 (July 2026) and a collaboration result with OpenAI (May 2025). No revenue, pipeline milestones or clinical results are disclosed.
Latest developments
The most recent items listed on the company website are dated July 7, 2026 (coverage of developing an Alzheimer's treatment with AI) and July 3, 2026 (Sanofi announcing the out-licensing of SAR444500 to Babylon). Caplight recorded a market signal on April 19, 2026 noting monthly website visitors grew 207% month-over-month to 3.2K, and places the company in the top 25% of tracked companies by its proprietary momentum index. The site carries a 2026 copyright notice.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Babylon Biosciences is an early-stage private company; F4 lists its stage as seed and Caplight reports total funding of $500,000 across an August 2024 seed round and an October 2024 accelerator round. Caplight identifies Integrated Biosciences (55% similarity), VeriSIM Life (53%) and Skape Bio (52%) as comparable companies by embedding similarity, while F4 lists Nabla Bio, Biomia, BioTax, Think Bioscience and Bit Bio as similar companies. No market share, revenue or competitive-position data are disclosed.
The sources' principal differentiation claim is the seniority and prior track record of the company's team and advisors in small-molecule drug discovery, expressed as aggregate counts of FDA-approved medicines, patents, clinical candidates and industry recognition, and as named prior drugs discovered by team members at other organizations. Caplight additionally associates the company with AI-driven and in silico drug discovery and clinical trial success prediction, and the company reports work with OpenAI on predicting clinical trial success. No proprietary platform, data asset or intellectual property of Babylon Biosciences itself is described in the sources.
Technology
Caplight describes the company as developing small-molecule therapeutics for diseases of the brain and tags it with keywords including drug discovery, AI-driven and in silico drug discovery, predictive modeling, clinical trial prediction, diagnostic assay, biological reagents and biotech lab services, positioning its AI layer at the application level. The company's own news feed references a May 14, 2025 announcement with OpenAI on AI-driven prediction of clinical trial success and a July 2026 item on developing an Alzheimer's treatment in the context of AI. The sources do not detail the underlying models, chemistry platform or targets.
Go-to-market
The sources do not describe a sales or commercialization approach. Observable activity consists of in-licensing an asset from a large pharmaceutical company (Sanofi's SAR444500, per the company's July 2026 news item), a collaboration announcement with OpenAI, and participation in Mission BioCapital's Platinum Program.
Caplight classifies the company as B2B with a services-and-consulting customer profile; F4 also labels the model B2B biotech. The therapeutic focus described is patients with diseases of the brain, including Alzheimer's disease. No named customers or partners beyond OpenAI and Sanofi are identified.
Geography
Caplight lists the headquarters as San Francisco, California, United States. No other locations are identified in the sources.
History
Caplight records a founding year of 2023 and a San Francisco headquarters. Funding activity listed includes a seed round dated August 2024 and an accelerator round dated October 30, 2024, the latter coinciding with Mission BioCapital's announcement of the first winners of its Platinum Program, which the company lists in its news feed. Subsequent company-posted milestones include a May 2025 announcement with OpenAI on AI-driven prediction of clinical trial success, a February 2026 CEO interview about the company's Alzheimer's work, a July 2026 note that Sanofi out-licensed SAR444500 to Babylon, and a July 2026 item on developing an Alzheimer's treatment using AI.
Risks & controversies
No controversies or risk events involving Babylon Biosciences appear in the sources. Note that several retrieved documents concern Babylon Health, an unrelated UK-based telehealth company that entered insolvency proceedings in 2023; those sources were excluded from this profile. Structural risks evident from the record itself include very limited disclosed funding ($500,000 per Caplight), a small team (employee range of 10), an absence of any disclosed clinical pipeline or trial data, and a public profile that rests largely on team members' prior achievements at other companies.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlapCompanies competing with Babylon Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsCompany news listing titled 'Developing a treatment for Alzheimer's in the world of AI'.
Company news listing stating that Sanofi announced the out-licensing of the asset SAR444500 to Babylon; terms not disclosed on the site.
Company news listing referencing an interview with the CEO about Babylon's work on Alzheimer's disease.
Company news listing announcing a breakthrough with OpenAI in AI-driven prediction of clinical trial success; no further detail provided on the company site.
Babylon Biosciences was included in Mission BioCapital's announcement of the first winners of its Platinum Program and inaugural service sponsors; Caplight records an accelerator round dated the same day.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Babylon Biosciencesbabylon.bio · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Babylon Biosciences do?
- San Francisco biotech developing small-molecule therapeutics for brain diseases such as Alzheimer's.
- Who are Babylon Biosciences's investors?
- Babylon Biosciences's investors include Backwards Capital, K5 Global, Launch House, Long Journey Ventures, Metaplanet, a16z crypto, Paradigm.